Categories: News

Introducing Kamvas Pro 27 (144Hz): The Industry’s First 27-inch 4K Pen Display with a 144Hz Refresh Rate

LAS VEGAS, Dec. 1, 2025 /PRNewswire/ — Huion, the industry-leading manufacturer of digital tablets, is excited to announce the Kamvas Pro 27 (144Hz) pen display. This new edition builds on the iconic Kamvas Gen 3 features we’ve come to know, including PenTech 4.0 (with 16,384 levels of pressure sensitivity) and high color accuracy, while also enhancing the refresh rate to 144Hz, updating the glass to the latest anti-fingerprint Canvas Glass 3.0 technology, and expanding the color gamut.

- Advertisement -

A high refresh rate plays a crucial role in creative fields. It makes the experience of digital drawing feel as close to drawing on real paper as possible, allowing creators to immerse themselves fully in the creative process. With the 144Hz refresh rate, creators can enjoy ultra-smooth visuals, seamless pen input, and real-time responsiveness. These are especially important for fast-paced animation or high-detail work.

- Advertisement -

For example, when working on frame-by-frame animation, animators need to repeatedly preview sequences. The 144Hz screen delivers incredibly smooth and clear visuals, making it easier to spot any unnatural motion, stuttering, or jitter, and enabling precise adjustments.

- Advertisement -

Paired with 4K resolution, the Kamvas Pro 27 (144Hz) ensures every detail of your artwork is rendered in stunning clarity. Multi-touch functionality makes interaction more intuitive and enjoyable, enhancing your work efficiency. The included PW600 and PW600S pens, powered by PenTech 4.0, provide even lines and precise cursor tracking, and feel like a real pen or brush.

- Advertisement -

Additionally, the Kamvas Pro 27 (144Hz) boasts an expansive color gamut, covering 99% sRGB, 98% Adobe RGB, 98% DCI-P3, and the newly added Display P3 color space (98%). Whether you’re working on illustrations, motion graphics, commercials, or 3D projects, it delivers vibrant and cinematic-quality visuals with rich hues and contrast.

- Advertisement -

As the industry’s first 27-inch 4K pen display with a 144Hz refresh rate, the Kamvas Pro 27(144Hz) is a highly competitive product in the market. For more product information, visit www.huion.com.

- Advertisement -

About Huion

- Advertisement -

Huion is dedicated to developing innovative digital ink solutions and cutting-edge creative tools, including pen tablets, pen displays, and pen computers, for all forms of digital art.

- Advertisement -

 

- Advertisement -

Photo – https://mma.prnewswire.com/media/2811472/Kamvas_Pro_27__144Hz.jpg
Photo – https://mma.prnewswire.com/media/2811473/Kamvas_Pro_27__144Hz__01.jpg
Logo – https://mma.prnewswire.com/media/1584078/5597057/LOGO_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/introducing-kamvas-pro-27-144hz-the-industrys-first-27-inch-4k-pen-display-with-a-144hz-refresh-rate-302628730.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

7 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

7 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

7 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

7 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

7 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

7 hours ago